Biologics are one of the fastest growing category of drugs—and one of the most expensive—making it challenging to balance cost with safety and efficacy. And it’s even more challenging to incorporate unbranded biologics and biosimilars into benefits plans. Gus Georgiadis, Area President, Gallagher Benefit Services, cuts through the confusion on how these therapies work and outlines what benefits managers need to know.
Listen to this podcast to get answers to the following questions: